Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Microbot Medical Inc. - Common Stock (NQ:MBOT)

2.021 -0.039 (-1.88%)
Streaming Delayed Price Updated: 12:07 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Microbot Medical Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Microbot Medical®’s LIBERTY® Endovascular Robotic System Continues to Expand Market Visibility; Being Featured at an Industry Leading Innovation Conference
Global Robotic Leaders Convene to Discuss & Highlight Surgical Advancements of the Next Decade with a Special Focus on the Endovascular Space 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical®’s LIBERTY® Endovascular Robotic System Highlighted at a Leading Vascular Disease Management Conference
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® to Leverage Current Users Experience of the LIBERTY® Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption
Participating at the Society of Interventional Oncology Conference Will Allow the Company to Share Practical Insights and Personal Experiences 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Continues its 2025 Momentum; Announces Key 2026 Milestones
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Announces Emory University Hospital as the First Hospital in the World to Adopt the New LIBERTY® Endovascular Robotic System
Adoption of LIBERTY is Consistent with Emory’s Commitment to the Growing and Evolving Field of Interventional Radiology 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S.
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® to Commercially Debut the LIBERTY® System at The Symposium on Clinical Interventional Oncology Annual Meeting
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular Robotic System
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
$25.2 million in first closing, $1.2 million in second closing and $2.8 million in third and final closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon... 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Miocrbot Medical® CEO to Discuss Recent FDA Clearance of the LIBERTY® Endovascular Robotic System
Livestream Interview Can be Viewed on September 24th at 10:45am ET at Benzinga All Access Live 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Announces First Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
$25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term... 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for Up to $92.2 Million in Gross Proceeds
$25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term... 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
REMINDER: Microbot Medical to Highlight FDA 510(k) Clearance of the LIBERTY Endovascular Robotic System at the H.C. Wainwright Annual Investor Conference
Live Presentation to be Webcast Today at 9am ET 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Receives FDA 510(k) Clearance for Its LIBERTY® Endovascular Robotic System
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Granted U.S. Patent that Significantly Expands Potential Market Applications
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
DIH Appoints Scott R. Burell to DIH Holding US, Inc. Board of Directors
From DIH Holding US, Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Receives Non-Dilutive Grant to Enhance Operational Capabilities
Strengthens Balance Sheet and Continues Commercialization Readiness Plans for the LIBERTY® System as it Nears FDA Marketing Clearance Decision 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales
Company Continues to Strengthen Organizational Infrastructure with Success-Driven Medical Device Veteran 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® to Open Inaugural Endovascular Robotics Session at the Society of Robotic Surgery Annual Meeting
Leading Endovascular Innovators to Highlight Emergence and Growth of Robotics in the Specialty 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Added to the Russell Microcap® Index
Automatic inclusion in the appropriate growth and value style indexes 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Strengthens Global IP Portfolio with Newly Granted Patent in China
Significant Development Supports Long-Term Global Commercial Strategy of the LIBERTY® System 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Continues to Strengthen Commercial Capabilities in Preparation for the anticipated Q3 2025 Launch of its LIBERTY® Endovascular Robotic System
The addition of the head of Sales Operations & Analytics aims to strengthen sales infrastructure and launch execution 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Selected for Preliminary Inclusion to Russell Microcap® Index
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Bolsters Commercial Leadership Team with the Addition of Experienced Healthcare Officers
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Global Robotic Exoskeleton Market Size Expected to Reach $30 Billion By 2032 as A.I. Influence Disrupts the Industry
EQNX::TICKER_START (NYSE:KULR),(NASDAQ:CHRW),(NYSE:PBI),(NYSE:GXO),(NASDAQ:MBOT) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
REMINDER: Microbot Medical Announces Data from the Company’s ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting
Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second Quarter 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Global Robotic Exoskeleton Market Size Expected to Reach $30 Billion By 2032 as A.I. Influence Disrupts the Industry
From FN Media Group LLC
Via GlobeNewswire
News headline image
Microbot Medical Appoints Seasoned Endovascular Sales Executive to Lead its U.S. Sales Activities for LIBERTY® Endovascular Robotic System
From Microbot Medical Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.